NCT00622674View on ClinicalTrials.gov

Bortezomib and Cetuximab in Treating Patients With Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

November 30, 2005

Primary Completion Date

August 31, 2009

Study Completion Date

February 28, 2010

Conditions
Breast CancerColorectal CancerHead and Neck CancerKidney CancerLung CancerPancreatic CancerSarcomaUnspecified Adult Solid Tumor, Protocol Specific
Interventions
BIOLOGICAL

cetuximab

A loading dose of cetuximab will be given on day 1 (400 mg/m2) followed by a weekly dose of 250 mg/m2.

DRUG

bortezomib

The starting dose of bortezomib will be 1.3 mg/m2 with a 0.1 increment increase with each successive dose level to a maximum of 2.0 mg/m2.

Trial Locations (1)

55455

Masonic Cancer Center at University of Minnesota, Minneapolis

All Listed Sponsors
lead

Masonic Cancer Center, University of Minnesota

OTHER

NCT00622674 - Bortezomib and Cetuximab in Treating Patients With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter